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Purpose: Genetic risk assessment is becoming an important component of clinical
decision-making. Genetic Risk Scores (GRSs) allow the composite assessment of genetic
risk in complex traits. A technically and clinically pertinent question is how to most easily
and effectively combine a GRS with an assessment of clinical risk derived from established
non-genetic risk factors as well as to clearly present this information to patient and health
care providers.
Materials and Methods: We illustrate a means to combine a GRS with an independent
assessment of clinical risk using a log-link function. We apply the method to the prediction
of coronary heart disease (CHD) in the Atherosclerosis Risk in Communities (ARIC) cohort.
We evaluate different constructions based on metrics of effect change, discrimination, and
calibration.
Results: The addition of a GRS to a clinical risk score (CRS) improves both discrimination
and calibration for CHD in ARIC. Results are similar regardless of whether external vs.
internal coefficients are used for the CRS, risk factor single nucleotide polymorphisms
(SNPs) are included in the GRS, or subjects with diabetes at baseline are excluded. We
outline how to report the construction and the performance of a GRS using our method
and illustrate a means to present genetic risk information to subjects and/or their health
care provider.
Conclusion: The proposed method facilitates the standardized incorporation of a GRS in
risk assessment.
Keywords: genetic risk scores, personalized medicine, coronary heart disease, electronic health records
INTRODUCTION
As genotyping technologies become more common, the inter-
pretation of genetic risk is becoming a bigger component of
clinical decision-making. A particular challenge is the interpre-
tation of such genetic information in the context of other clinical
health information. Recently, the electronic MEdical Records and
GEnomics (eMERGE) network outlined challenges and opportu-
nities for integrating genetic data into an electronic health records
(De Jager et al., 2009) system. One issue identified was the auto-
mated interpretation of genetic data (Gottesman et al., 2013; Kho
et al., 2013; Marsolo and Spooner, 2013; Ury, 2013). The sheer
size of genomic data provides many interpretative challenges, par-
ticularly in the age of whole genome sequencing with billions of
variant base pairs, many of which are de novo.
Genetic Risk Scores (GRSs) are one tool for automating the
rendition of one’s genetic risk. They provide a means to aggre-
gate the health related risk of a collection of genetic alleles into
a single number, which can then be used for risk assessment.
Using results from genome-wide association studies, one typi-
cally combines the observed (or meta-analyzed) log odds-ratio
of the risk associated single nucleotide polymorphisms (SNPs).
Such scores have been formulated for a variety of complex traits
including coronary heart disease (CHD), diabetes, multiple scle-
rosis and schizophrenia (De Jager et al., 2009; Purcell et al.,
2009; Thanassoulis et al., 2012). Overall, GRSs have been shown
to modestly improve risk assessment using both traditional and
more recently developed model performance metrics (Cook,
2007; Steyerberg et al., 2012).
We anticipate individuals will increasingly approach their
physicians with questions regarding their genetic risk of common
diseases as high density genetic profiling becomes progressively
more routinely available. In this paper, we consider the emerging
scenario where a hospital system decides to incorporate genetic
data into their EHR for the purposes of clinical risk assessment.
One obstacle hampering the effective incorporation of GRSs into
clinical practice is the lack of clarity in how to most readily
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combine a GRS with a clinical risk assessment. Here, we describe
a relatively straightforward method to combine genetic infor-
mation at established susceptibility loci with a non-genetic risk
prediction tool. We illustrate this approach in the context of CHD
using a GRS constructed from themost promising association sig-
nals reported to date for this disease. We emphasize that the goal
of this study is neither to validate the utility of a GRS in risk pre-
diction nor to assess the best way to construct a GRS but rather to
demonstrate how one might interpret a GRS and easily incorpo-
rate it into a clinical risk assessment. A GRS can be constructed in
a variety of ways (Schrodi et al., 2014). One may select SNPs and
define their respective high-risk allele either through the investi-
gation of SNP effects within the cohort itself or within external
studies that are typically much larger but not necessarily prospec-
tive in nature. One may also weigh the high-risk allele by its
effect size observed internally or externally. In this study, we used
the weighted approach deriving both the SNPs and weights from
external sources. Lastly, we illustrate one way to present risk pre-
diction analyses incorporating GRSs to patients and health care
providers.
METHODS
SNP SELECTION ANDWEIGHTING
We selected SNPs from the most recent and largest multi–
stage meta-analysis of GWAS for coronary artery disease con-
ducted by the CARDIoGRAMplusC4D consortium to construct
the GRS (CARDIoGRAMplusC4D Consortium et al., 2013).
The study included 63,746 cases and 130,681 controls. The
vast majority of the subjects included in this meta-analysis
reported white/European ancestry. The meta-analysis added 15
new CHD susceptibility loci and confirmed nearly all loci that
had previously reached genome-wide significance. The inves-
tigators also identified secondary signals at four established
loci. Supplementary Table 9 of the CARDIoGRAMplusC4D
manuscript lists all uncorrelated SNPs (r2 < 0.2) with an
estimated FDR < 5% (CARDIoGRAMplusC4D Consortium
et al., 2013). From this list, we selected the 50 SNPs iden-
tified by the consortium as validated SNPs because they had
reached a genome-wide level of statistical significance in either
the CARDIOGRAMplusC4D meta-analysis or in any previous
GWAS.
We expect a subset of SNPs to be influencing the risk of CHD
through traditional risk factors as the CARDIOGRAMplusC4D
meta-analysis adjusted only for age and sex. Indeed, the
CARDIoGRAMplusC4D investigators determined that 12 and 5
of these 50 SNPs likely influence CHD risk through effects on
lipids and blood pressure based on their strong association with
these traits in the Global Lipids Genetics Consortium and the
International Consortium of Blood Pressure meta-analyses of
GWAS, respectively (CARDIoGRAMplusC4D Consortium et al.,
2013). For the purposes of this study, we classified these 17 SNPs
as “risk factor SNPs.” The remaining 33 SNPs were classified as
“non-risk factor SNPs.”
PROSPECTIVE COHORT FOR TESTING GENETIC RISK SCORES
We selected the AtherosclerosisRisk in Communities Study
(ARIC) study to develop and test a GRS constructed with the
50 SNPs of interest. The ARIC Study is an ongoing prospective
investigation of atherosclerosis and its clinical sequelae involving
15,792 white and black persons aged 45–64 years at recruit-
ment (1987–1989). Detailed descriptions of the study designs,
IRB consent process, sampling procedures, methods, definitions
of cardiovascular outcomes, and approach to statistical analyses is
published elsewhere (White et al., 1996; Volcik et al., 2006).
We selected ARIC for several reasons including the availability
of individual level genome-wide data for all participants through
the National Institutes of Health (National Human Genome
Research Institute) controlled access database of Genotypes and
Phenotypes (dbGaP), a prolonged follow up with > 1000 inci-
dent cases, and no overlap of incident cases with prevalent cases
that were included in the CARDIoGRAMplusC4D consortium
study (CARDIoGRAMplusC4D Consortium et al., 2013). The
Affymetrix 6.0 array was used to genotype all participants of the
ARIC study.
All white/Europeans without a history of CHD, myocardial
infarction, or heart failure at baseline among the ARIC cohort
subjects in dbGAP were eligible for study inclusion. Incident
CHDwas defined by the recording for the first time of either non-
fatal or fatal myocardial infarction (“mi04,” “fatchd04”), CHD
related revascularization procedure (“in_by04p”), or silent MI
detected by ECG (“in_04s”).
The outcome of interest was incident CHD within 10 years.
Those without a positive event who died or were lost to follow up
prior to their 10th year anniversary of follow up were removed
from analysis. All others were deemed event free at 10-years
regardless of whether they developed incident CHD sometime
after their 10 year anniversary of follow up.
CLINICAL RISK SCORE ASSESSMENT
We calculated two clinical risk scores (CRSs) to assess clinical risk
at 10 years. The first was the well-known “external” Framingham
Risk Score (FRS) for 10-year risk of CHD. The score is based
on one’s gender, age, total cholesterol, HDL cholesterol, blood
pressure, and diabetes and smoking status. Ten-year risk of CHD
was calculated using the published regression coefficients (Wilson
et al., 1998). The second score was developed “internally” within
the ARIC and tested and incorporated the same FRS risk factor
variables using cross-validation (see below). Subjects with one or
more missing FRS risk factors were excluded from the analysis.
IMPUTATION OF ARIC RAW GENOTYPE DATA TO 1000 GENOMES
We imputed individual level genotype data from ARIC to the
latest build of the 1000 genomes project (1 kGP) used a hid-
den Markov model to minimize the need to use proxy SNPs in
the construction of the GRS (Abecasis et al., 2012; Howie et al.,
2012). We first phased each chromosome using MaCH (v1.0.16)
by running 20 rounds of theMarkov sampler and considering 200
haplotypes (states) when updating each individual. We then used
phased haplotypes in each chromosome and the latest release of
the 1 kGPcosmopolitan panel (version 3 March 2012 release, 246
AFR + 181 AMR + 286 ASN + 379 EUR) to impute all SNPs in
the cosmopolitan panel using the OpenMP protocol based multi-
threaded version of Minimac (v4.6) with 20 rounds and 300 states
for each chromosome. Genotyped SNPs used for imputation were
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restricted to those with the following features: MAF > 0.1%,
missing data per SNP < 2%, and Hardy-Weinberg equilibrium
(HWE) p > 10−6. Of the 841,820 autosomal genotyped mark-
ers, 543,653 passed the initial quality filters and were used for the
imputation of over 37 million SNPs in ARIC. We used GTOOL
(Genetics Software Suite, (c) 2007, The University of Oxford) to
convert Minimac dosage files to best guess genotype calls.
GRS CONSTRUCTION
We calculated the GRS for an individual in the typical approach
as a weighted sum of the number of high risk alleles [1].
GRS =
50∑
i∈GRS
ωi
2∑
j=1
RAij (1)
where the inside summation, RAij, is the count of high risk alle-
les and the weight, wi, is the meta-analyzed log odds-ratio for
SNP i. We used the corresponding “combined beta” (i.e., the beta
across the stage 1 and 2 CARDIOGRAMplusC4D meta-analysis)
to weigh the SNP when constructing the GRS. We carefully iden-
tified the high-risk allele for each SNP. We used the GTOOL
genotype calls to count high-risk alleles for all SNPs in each indi-
vidual after first dropping SNPs with a low imputation quality
(r2 < 0.3).
There are two primary assumptions in such a construc-
tion. Since this summation is over marginal effects, each effect
is assumed to be independent. The second is that the effects
are linearly additive, i.e., there are no interactions. For the
first assumption, care was taken to select SNPs that are not
in linkage disequilibrium (i.e., correlated) with one another in
white/European descent participants (r2 < 0.2). While the sec-
ond assumption is likely violated, it is also reasonable to assume
that marginal effects capture a majority of genetic risk for CHD
(Zdravkovic et al., 2002; Speed et al., 2012). When using the GRS
we standardize it to have a mean of 0 and standard deviation of 1.
COMBINING CLINICAL AND GENETIC RISK
We present a simple and easy way to combine one’s CRS and GRS
by using the following model [2]:
log (P(CHD |Clinical &Genetic Factors )) = α + β1CRS
+β2GRS (2)
This is a standard generalized linear model, where the outcome is
a binary (0–1) indicator for incident CHD within 10 years and
the predictor variables are the CRS and GRS, respectively. The
CRS represents either a calculated risk due to non-genetic clin-
ical factors (as in FRS) or a summation over multiple clinical
risk factors (when using internal coefficients). We emphasize the
use of a log link function instead of the more frequently used
logistic link function (as in logistic regression). This allows the
two coefficients of interest (β1 and β2) to represent log relative
risks (RR), making the following transformation more straight-
forward. However, we note that using the logistic link one could
perform a similar transformation. After exponentiating equation
[2], we obtain:
P (CHD |Clinical &Genetic ) = eα+β1CRS × eβ2GRS
= P (CHD |Clinical ) × RRGRS(GRS)(3)
In the second line, we have combined the intercept (α) with the
effect due to clinical factors. This is generally well captured by a
CRS (like FRS) that incorporates the prevalence of disease in the
general population. Since we are multiplying the estimated effects
for the GRS and CRS, the primary assumption is that the GRS is
linearly independent of the CRS. This assumption would poten-
tially be violated if the GRS consisted of SNPs that were thought to
act entirely or largely through effects on non-genetic clinical risk
factors measured at baseline. However, the impact is mitigated by
controlling for the CRS while estimating the RR for the GRS in
equation [2].
Therefore, to calculate a probability of CHD based on clinical
and genetic factors, we must:
(1) Estimate the RR for a one-unit change in GRS on the proba-
bility of CHD within 10 years controlled for CRS.
(2) For a given individual:
(a) Calculate the probability of CHD based on clinical fac-
tors via a FRS or Internal Score
(b) Calculate the GRS (based on equation 1) and standardize
it using population mean and standard deviation (SD)
(c) Multiply the probability from (a) by the RR from (1)
raised to the value of standardized GRS from (b) (based
on second line of Equation 3)
EVALUATION OF PERFORMANCE OF RISK SCORES
We used 10-fold cross-validation to test both the CRS and GRS,
dividing the cohort into a series of independent training and test
sets. We created a series of updated risk scores:
(1) A CRS based solely on the FRS (no genetic information
considered)
(2) A CRS based solely on the internal coefficients (no genetic
information considered)
(3) A CRS updated with a GRS constructed using all SNPs of
interest that were either well genotyped or well imputed in
ARIC.
(4) A CRS updated with a GRS constructed using only “non–risk
factor” SNPs among the SNPs in (3)
(5) A CRS updated with a GRS constructed using only “risk
factor” SNPs among the SNPs in (3)
The overall relative risk for a standardized one-unit change in
GRS was estimated while incorporating the CRS (either FRS or
internal). Within each of the 10-folds, the training (9/10) and test
(1/10), we created a standardized score based on the mean and
standard deviation from the training set. The models were esti-
mated on the training split and applied to the test split. We used
three forms of assessment. First, we calculated the c-statistic to
assess discrimination of the various risk scores. Discrimination
refers to a model’s ability to separate subjects into distinct groups,
in this case, those with CHD from those without. Secondly, we
calculated the RR for a one standard deviation change in GRS.
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Finally, we calculated the calibration slope to assess each models
overall calibration (Kramer and Zimmerman, 2007). The calibra-
tion of a model is the extent to which the predicted probability
reflects the true underlying probability. The calibration slope
is a more interpretable statistic than the more typical Hosmer-
Lemeshow statistic, representing the degree of miscalibration
(Crowson et al., 2014). A calibration slope of 1.0 indicates per-
fect calibration while values less than 1.0 suggest over-fitting and
above 1.0 poorer calibration. For example a calibration slope of
2.0 indicates a two-fold increase in miscalibration. We chose not
to assess our models using the Net Reclassification Index (NRI)
or the clinical NRI due to recent concerns about the utility and
validity of this metric combined with changing clinical guidelines
for cardiovascular disease risk assessment (Paynter and Cook,
2012; Ridker and Cook, 2013; Goff et al., 2014; Kerr et al., 2014;
Muntner et al., 2014).
In a sensitivity analysis, we repeated the above comparisons
but restricted the cohort to those without prevalent diabetes. We
also considered a risk predictionmodel using only a GRS adjusted
for age and gender and no other clinical risk factors to provide a
perspective on the overall impact of clinical risk factors compared
to the genetic risk score. Finally, we assessed the potential for
population stratification by performing a principal components
analysis (PCA) with 741 ancestry informative markers (AIMs)
using EIGENTRAT (Price et al., 2006) followed by a regression
of CHD status onto all significant components, adjusted for the
clinical factors.
All analyses were performed in R 3.0.1 (R Core Team, 2014).
RISK REPORTS
Using the generated information, we illustrate one means to pro-
vide a risk report about an individual’s clinical and genetic risk of
disease. Three key pieces of information are included:
(1) The number of risk alleles
(2) How the individual’s GRS compares to the distribution of
GRSs in a comparative population.
(3) The change in one’s overall risk after accounting for genetic
risk
The number of risk alleles represents a simple count of the num-
ber of alleles that have been associated with an increased risk of
CHD. The GRS comparison to the general population is based
on the individual’s standardized GRS. Finally the updated risk is
calculated from equation (3). A fourth piece of information that
can be included in the risk report is a statement of how the indi-
vidual’s change in overall risk after accounting for genetic risk
influences clinical management. This may be based on some well-
accepted guidelines whose recommendations can be easily and
reliably automated.
RESULTS
ARIC COHORT EXCLUSIONS
Of the 12,771 from the ARIC cohort with phenotypic and geno-
typic data, 9633 (75%) were white/European (see Figure 1).
Among the remaining subjects, 721 (7.5%) had a history of CHD
or CHF at baseline and were excluded from further analysis.
FIGURE 1 | Atherosclerosis Risk in Communities (ARIC) cohort
inclusion and exclusion criteria applied to data obtained from the
NCBI’s database of genotypes and phenotypes (dbGAP).
Lastly, we excluded 380 people who were lost to follow-up or died
of non-CHD related factors within 10 years and 41 people with
missing covariate information, comprising a final cohort of 8491.
Table 1 shows the baseline characteristics for the ARIC subcohort
used in our analyses. The predicted 10-year risk of developing
CHD based on the FRS in this subcohort is 7.4% (interquartile
range 4.3–12.3%). This predicted risk coincided very well with
the observed proportion that developed CHD (7.3%).
RISK SCORES
The 50 SNPs of interest for construction of the GRS are listed in
supplemental Table 1 along with their relationship to risk factors,
weights, high risk allele based on the 1000G reference + strand,
imputation quality metrics, and genotype quality control met-
rics. Of the 50 SNPs, five had an estimated imputation accuracy
r2 < 0.3. These five SNPs, which included two SNPs in the APOE
locus, were dropped from the GRS. The average r2 of the remain-
ing 45 SNPs was 0.857 (range: 0.361–0.999). The unstandardized
mean value of the GRS was 3.17 (SD: 0.347) for all SNPs, 1.95
(0.307) for non-risk factor SNPs alone, and 1.22 (0.160) for risk
factor SNPs alone. Interestingly, there was no difference in the
unstandardized scores and standard deviations derived from the
entire cohort compared to the scores derived from the subset of
subjects without diabetes at baseline when considering up to three
significant figures. After standardization, the mean and SD of all
GRS was 0 and 1 as expected.
PERFORMANCE OF RISK SCORES AND SENSITIVITY ANALYSES
Table 2 summarizes the c-statistics for the 8 risk scores (as well
as the age and sex only scores) and the associated RR for a 1-unit
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change in the risk score. Adding a GRS improves overall risk dis-
crimination. As expected, the risk score using internal weights
demonstrates the best discrimination and calibration. The cali-
bration slope statistics improved (i.e., they become smaller) with
the addition of the GRS. A GRS restricted to SNPs that were not
related to traditional risk factors performed essentially equally
well to a GRS constructed from all SNPs combined, adding about
1 point to the c-statistic. This result suggests that the addition
of CHD SNPs that are associated with CHD as well as risk fac-
tors will neither aid nor hurt risk assessment. Finally, creating a
Table 1 | Characteristics of the ARIC subcohort used in analyses
(n = 8491).
mean (IQR)
Age (years) 54 (49,59)
SBP (mm/Hg) 116 (106, 128)
DBP (mm/Hg) 71 (65, 78)
HDL (mg/dL) 48 (39, 61)
TC (mg/dL) 211 (187, 238)
Count (%)
white/European 8491 (100)
Male 3848 (45)
Diabetes 626 (7.4)
SMOKING STATUS
Current 2010 (24)
Former 2914 (34)
Never 3567 (42)
IQR, inter-quartile range; SBP, Systolic Blood Pressure; DBP, Diastolic Blood
Pressure; HDL, High-Density Lipoprotein Cholesterol; TC, Total Cholesterol.
risk score only with age and sex performed worse than the risk
scores with additional clinical factors. However, the improvement
in both discrimination and calibration after adding the GRS is
comparable to the scores with the full clinical factors.
Table 3 summarizes the same risk score comparisons presented
in Table 2 after removing 626 ARIC participants (7.4%) who
reported having diabetes at baseline. We found the general trend
of results to be similar to the full cohort despite a smaller sample
size. There was amodest improvement in discrimination by about
1 point in the c-statistic as well as improvement in calibration.
PCA revealed eight significant principal components. Only
component 3 had a nominal association with CHD (p = 0.023,
not corrected for number of components tested) suggesting that
the addition of PCs into our model for this sample of self
reported white/Europeans would not materially influence our
results (Supplemental Table 2).
RISK REPORTS
In Figure 2, we illustrate a sample report for an individual to show
how the addition of a GRS to themodel can change the risk assess-
ment that may be used for clinical decision-making. The goal of
this report would be to facilitate a conversation around the risk
of CHD due to genetics above beyond the known clinical risk
factors. At baseline, the participant’s estimated risk of CHD at
10 years is 5.5% based on traditional Framingham risk factors.
The participant carries 49 of 90 potential risk alleles resulting
in a weighted standardized GRS of 1.26 which places the indi-
vidual in the 89th percentile of genetic risk (i.e., only 11% of
the population has a higher risk based on alleles inherited at
these 45 SNPs). Combining the participant’s genetic risk with
their clinical risk results in a final predicted risk of CHD of 7.6%
given each SD increase in one’s GRS leads to a 38% increase in
risk of CHD (Table 2). This magnitude of increased risk may
Table 2 | Relative Risks and discrimination metrics for a genetic risk score derived from 50 genome wide significant susceptibility alleles for
CHD in the full ARIC sample (n = 8491) of white/Europeans subjects.
Relative Risk (95% CI) C-statistic* Calibration Slope
USING FRS FOR CLINICAL RISK SCORE
FRS alone – 75.8 7.32
+ full GRS 1.29 (1.20, 1.40) 76.8 6.26
+ GRS restricted to non-risk factor SNPs 1.29 (1.20, 1.40) 76.8 6.29
+ GRS restricted to risk factor SNPs 1.06 (0.98, 1.14) 75.8 7.22
USING INTERNAL COEFFICIENTS FOR CLINICAL RISK SCORE
Internal coefficients alone – 77.3 4.34
+ full GRS 1.28 (1.19,1.38) 78.3 4.17
+ GRS restricted to non-risk factor SNPs 1.29 (1.20, 1.39) 78.3 4.18
+ GRS restricted to risk factor SNPs 1.05 (0.97, 1.13) 77.4 4.31
USING ONLY AGE AND SEX
Internal coefficients alone – 68.9 11.22
+ full GRS 1.31 (1.22,1.41) 70.4 9.26
+ GRS restricted to non-risk factor SNPs 1.29 (1.20,1.39) 70.1 9.69
+ GRS restricted to risk factor SNPs 1.11 (1.03, 1.20) 69.2 10.79
CHD, Coronary Heart Disease; ARIC, Atherosclerosis Risk in Communities; FRS, Framingham Risk score; SNPs, Single Nucleotide Polymorphism; GRS, genetic risk
score; *performance of second model listed to first model listed.
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Table 3 | Relative Risks and discrimination metrics for a genetic risk score derived from 50 genome wide significant susceptibility alleles for
CHD in the ARIC subset of white/Europeans with no diabetes at baseline (n = 7865).
Relative Risk (95% CI) C-statistic* Calibration Slope
USING FRS FOR CLINICAL RISK SCORE
FRS alone – 75.2 8.84
+ full GRS 1.28 (1.17, 1.39) 76.2 7.02
+ GRS restricted to non-risk factor SNPs 1.30 (1.20, 1.41) 76.3 7.22
+ GRS restricted to risk factor SNPs 1.02 (0.94, 1.11) 75.1 8.67
USING INTERNAL COEFFICIENTS FOR CLINICAL RISK SCORE
Internal coefficients alone – 76.7 6.11
+ full GRS 1.28 (1.18, 1.39) 77.6 5.39
+ GRS restricted to non-risk factor SNPs 1.30 (1.20, 1.42) 77.7 5.40
+ GRS restricted to risk factor SNPs 1.03 (0.95, 1.12) 76.6 6.00
USING ONLY AGE AND GENDER
Internal coefficients alone – 70.5 12.86
+ full GRS 1.30 (1.20,1.41) 71.8 10.49
+ GRS restricted to non-risk factor SNPs 1.28 (1.18,1.39) 71.6 10.92
+ GRS restricted to risk factor SNPs 1.10 (1.01, 1.19) 70.7 12.44
CHD, Coronary Heart Disease; ARIC, Atherosclerosis Risk in Communities; FRS, Framingham Risk score; SNPs, Single Nucleotide Polymorphism; GRS, genetic risk
score; *performance of second model listed to first model listed.
FIGURE 2 | A sample report on CHD risk for an individual in the ARIC
study where the incorporation of genetic risk into the model of clinical
risk potentially influences clinical management based on current
guidelines.
affect the decision to treat this patient with statins (Stone et al.,
2014). Ultimately, this person did develop CHD suggesting that
the upward adjustment of risk was appropriate.
DISCUSSION
Genetic risk assessment will become an increasingly important
component of overall clinical risk assessment. In this context,
we ask the question: how can one most easily and effectively
incorporate a GRS into an existing clinical risk assessment of a
complex trait without compromising effectiveness? We present a
straightforward means to combine genetic risk with clinical risk
for a given disease where large-scale cohorts with prolonged fol-
low up exist and can be used to evaluate novel biomarkers. Our
approach requires knowing only three pieces of information: (1)
an individual’s GRS, (2) an individual’s CRS, and (3) the RR
associated with a 1-unit change in standardized GRS within the
cohort. Recent studies demonstrate an increasing clinical utility
of GRSs for CHD (Brautbar et al., 2012; Hughes et al., 2012;
Thanassoulis et al., 2012, 2013; Ganna et al., 2013; Tikkanen et al.,
2013). Using our method, we were able to confirm this trend
and demonstrate comparable or slightly improved discrimina-
tion even when comparing our results to the subset of studies
that used a GRS constructed with a similar set of SNPs (Brautbar
et al., 2012; Hughes et al., 2012; Thanassoulis et al., 2012; Ganna
et al., 2013; Thanassoulis et al., 2013; Tikkanen et al., 2013). We
should stress that evidence in the form of a well-executed clinical
trial that clearly demonstrates the value of a GRS in improving
CHD outcomes does not yet exist (Ioannidis and Tzoulaki, 2010).
Thus, we are not endorsing or negating the use of any specific
GRS in the primary prevention of CHD on the basis of our results.
Ongoing trials are examining the ability of information fromGRS
to improve outcomes (Knowles et al., 2012; Grant et al., 2013).
Our approach makes the simplifying assumption that the GRS
is largely independent of the CRS. This assumption appears rea-
sonable when one reliably restricts SNPs included in the GRS to
those influencing risk independent of variables included in the
CRS. We tested this assumption by creating two subset GRSs, one
restricted to SNPs associated with risk factors and one restricted
to SNPs that appear to influence risk of CHD independent of
all established risk factors. The non-risk factor GRS performed
noticeably better than the risk factor GRS confirming the conse-
quence of grossly violating this assumption. However, we detected
no notable difference between the non–risk factor GRS compared
to the full GRS. Thus, our approach appears robust to small
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violations of this assumption. This confirms others’ and our
experiences with GRSs that they are fairly robust to alternative
constructions (Purcell et al., 2009; Simonson et al., 2011).
An important consideration is the construction of the CRS.
We suspect that the ability to derive and make use of such inter-
nal coefficients will be facilitated by the increasing availability of
EHR with prolonged follow up of individuals receiving care as
members of a large-scale health maintenance organization (Ollier
et al., 2005; Palmer, 2007; Hoffmann et al., 2011a,b; Kaufman
et al., 2012). As expected, the use of internal coefficients led to
a slightly more effective CRS compared to the FRS that was devel-
oped in a different cohort than ARIC. Despite this observation,
we observed a negligible difference in the RR suggesting that per-
haps under some circumstances one can develop a GRS using an
internal CRS and apply it successfully in other cohorts (or vice-
versa). We also note that while the GRS improves calibration, the
risk scores overall are still poorly calibrated (> 1), particularly the
one using the FRS. This reflects other work that has shown that
the external coefficients applied to new populations can often lead
to poorly calibrated models (Ridker and Cook, 2013). Finally, the
risk score using only age and sex, not surprisingly, performed the
worst. Moreover, the improvement in both discrimination (68.9
vs. 77.3) and calibration (11.22 vs. 4.34) after adding additional
clinical factors is much greater than after the addition of a GRS
highlighting the relative importance of clinical factors collectively
at this point in time over the GRS in risk assessment for CHD.
However, one should not automatically assume that the current
GRS is not clinically useful given its AUC as it is in the same
range as that seen for the addition of any single modifiable tradi-
tional risk factor to a model that includes all other traditional risk
factors.
Several steps need to be followed in reporting of a GRS for
a trait using our method to facilitate its testing in additional
populations or to easily disseminate its use. First, the cohort in
whom the GRS was derived including the age range, sex dis-
tribution, risk factor profile, and the ethnicity of its members
must be clearly described. The GRS we present here is most rel-
evant to white/Europeans in the age range of 45 to 64 and free
of CHD at the time of clinical risk assessment given the eligibil-
ity criteria of the ARIC study and the fact that the SNPs used
in the GRS were derived from large-scale case-control studies
that included subjects in the same race/ethnic group and age
range (The ARIC Investigators, 1989; CARDIoGRAMplusC4D
Consortium et al., 2013). A different sets of SNPs with different
weights will likely be necessary for different race/ethnic groups
and possibly different age ranges although we expect substantial
overlap across race/ethnic groups in the genomic regions con-
tributing at least one SNP to the GRS (Knowles et al., 2012;
Ntzani et al., 2012). Second, one must reliably identify and report
which allele was coded as the high-risk allele as this allele is
not necessarily the minor allele. Errors in this context due to
inadvertent strand flipping either in the original study report-
ing the susceptibility variant or in the construction of the GRS
may have a profound negative impact on the performance of
the GRS. Third, the effect estimate for each SNP (generally a
log odds ratio) used in the weighting of the GRS should be
clearly presented. Lastly, the relative risk for a one-unit change
in GRS should be calculated and clearly presented along with
the mean and SD of the GRS to facilitate standardization of the
score.
We suggest a means to communicate the effect on risk of some-
one’s genetic data when combined with his or her clinical data.
Our presentation includes both a contextualization relative to the
general population and a statement on how one’s inherited vari-
ants update one’s clinical risk that is based strictly on traditional
non-genetic risk factor data. In ongoing clinical investigation, we
have applied a similar reporting system within a cardiology clinic
(Knowles et al., 2012). Such a report can easily be automated and
incorporated into an EHR.Moreover, it can also easily be updated
as new susceptibility SNPs are discovered and/or weights refined.
Given genome wide genotyping or sequencing is likely to become
routine in the near future, more research is needed to identify the
optimal way to communicate this information to subjects at risk
and health care providers.
Risk scores are likely to evolve over time and practice guide-
lines may adopt different risk scores. For example, the FRS that
we used here forms the basis of the Adult Treatment Panel III
(ATPIII) guidelines (2002). Recently, ACC/AHA released new car-
diovascular prevention guidelines, with new categories of risk,
with a change in the relevant endpoints and in the risk calculation
formulas (Goff et al., 2014; Stone et al., 2014). As of this writing,
there is still large controversy about the accuracy of the new calcu-
lations and the validity of the guidelines (Cook and Ridker, 2013;
Ridker and Cook, 2013; Ioannidis, 2014; Muntner et al., 2014).
Regardless, our proposed methods can be used to incorporate
GRS in any sets of non-genetic predictive models.
In conclusion, we present a simple but effective means to com-
bine a CRS with a GRS and illustrate one way to present such
information to an individual interested in understanding how
this genetic information influences their risk assessment and thus
potentially their clinical management. Furthermore, we highlight
information that should be included in all reports of GRSs to
facilitate the timely assessment of a new GRS by other investiga-
tors in additional populations or, alternatively, to easily incorpo-
rate it into clinical practice if its efficacy is no longer in question.
We expect the importance of such research to grow over time and
hope that future studies will more clearly delineate the optimal
way to implement a GRS and how to most effectively disseminate
a well-established GRS to patients and their health care providers.
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